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Aim of study: to evaluate the spectrum of pulmonary infection among Romanian CF
children.
Materials and Methods: study lot included 93 children, median age at diagnosis =
11.8 yrs, ranging from 3 month to 18 yr. Patients were classiﬁed in 4 age groups, as
follow: under 1 years old (n = 18), 1−3 yrs (n = 34), 3−7 yrs (n = 7), 7−18 years old
(n = 33). We have analyzed microbiological results obtained from: sputum samples,
throat swabs or pharingotracheal aspirates, for ﬁve years ago. The pursued pathogens
were: P. aeruginosa, S. aureus, MRSA, E. coli, Klebsiella sp, S. maltophilia, Aspergilus
fumigatus, Candida albicans. We could not determine Burkholderia cepacia complex.
Results: Table 1-Pathogens prevalence in CF children. Among study lot 19.35%
(18 patients) had infection with 2 or more pathogens.
Conclusions: P. aeruginosa is the most frequent pathogen in our lot study and its
prevalence is rising with age, while S. aureus predominates in babies. A.fumigatus has
is a signiﬁcant pathogen, also in older children. An important percentage of mixed
infection was registered, especially in delayed diagnosed children.
Table 1. Pathogens prevalence
Pathogens/Age group 3mo-1 yr 1−3 yrs 3−7 yrs 7−18 yrs
P. aeruginosa 6.45% 10.57% 34.44% 44.08%
S. aureus 25.8% 24.73% 30.10% 36.55%
MRSA 4.3% 5.37% 9.67% 7.52%
E. coli 11.82% 12.9% 4.30% 10.75%
Klebsiella sp 3.22% 5.36% 16.1% 13.97%
S. maltophilia – – 2.15% 3.22%
Aspergillus fumigatus 1.07% 4.30% 5.37% 9.67%
Candida albicans 15.05% 5.37% 11.82% 24.73%
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Background: Despite a large carriage rate of C. difﬁcile amongst cystic ﬁbrosis
(CF) patients, C. difﬁcile associated disease (CDAD) is rather rare. In case of
lung transplantation, the incidence and clinical aspects of CDAD in this patient
population is not well known.
Aim: The aim of the study was to compare the incidence and clinical characteristics
of CDAD between transplanted and non-transplanted CF subjects.
Methods: We reviewed the medical ﬁles of all CF patients who presented CDAD
from January 1998 to December 2004 and compared the incidence, clinical aspects
and outcome between non-transplanted and transplanted patients.
Results: Between 1998 and 2004, 106 CF patients were followed at our clinic of
whom 15 underwent lung transplantation before and 34 after 1998. The incidence
density of CDAD was higher in transplanted CF patients as compared with non-
transplanted CF patients (24.2 vs. 9.5 episodes/100000 patient-days; RR: 2.93
[1.41−6.08]; P = 0.0044). Diarrhoea was a very frequent feature, but was notably
absent in 20% of the cases. Rates of moderate and severe colitis were similar in both
groups. However, only transplanted CF patients developed complicated disease. Two
transplant recipients died because of CDAD.
Conclusion: CF patients, who undergo lung transplantation, are at a higher risk
for developing C. difﬁcile colitis and seem to present more often atypical and/or
complicated disease. CDAD should be part of differential diagnosis in case of
digestive symptoms, even in the absence of diarrhoea, and requires early treatment.
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B. pseudomallei is a rare isolate from CF patients outside endemic areas. This is
the ﬁrst report of B. pseudomallei recovered from the sputum of a CF patient in
Brazil.
This is a 17-year-old female with CF and concomitant diabetes mellitus (DM),
from Barra dos Bugres, MS, a tropical region of Brazil. Despite the diagnosis of
DM and chronic lung infection by P. aeruginosa since 1998, her pulmonary disease
was well controlled, as shown by normal lung function tests (FEV1 102%) and a
chest high resolution computer tomography with only minor bronchiectactic changes
(2002). Since 2004 her clinical condition gradually deteriorated, and she presented
frequent respiratory exacerbations, a FEV1 drop to 60%, and recurrent radiological
signs of infection and atelectasis, along with right upper lobe bronchiectasis. A
nonfermentative Gram-negative rod was recovered from her sputum in 2004 but
its precise identiﬁcation was inconclusive. Since 2005, however, B. pseudomallei
has been repeatedly identiﬁed (phenotypic tests conﬁrmed by PCR 16S rRNA gene
ampliﬁcation and sequencing) in her sputum. This organism has only rarely been
described in CF patients, most cases being related to travelling to an endemic
region. The patient has received many courses of antibiotics with clinical response;
eradication, however, was not achieved.
Conclusion: Isolation of B. pseudomallei from CF patients may be related to clinical
deterioration with consequent prognostic and therapeutical implications.
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Background: Nucleic acid tests are emerging as practical diagnostic tools for rapid
identiﬁcation and typing of BCC, also enabling direct detection of bacterial DNA
from patient’s sputum. In this study, sensitivity and diagnostic impact of recA PCR,
directly performed on sputum samples were evaluated.
Methods: Sputum samples from 28 CF patients were spiked with BCC reference
strain with approximate ﬁnal concentrations of 103 to 109 cfu/ml, having four
samples for each concentration. All sputa were processed with sputolysin and
nucleic acid extraction was performed by standart phenol-chloroform method. BCC
recA gene was ampliﬁed using BCR-1 and BCR-2 primers as previously described.
Results: BCC DNA was detected in 13 out of 28 (46.4%) samples. BCC concen-
trations lower than 106 cfu/ml in 12 sputum samples could not be ampliﬁed. All
samples (4/4) were positive in sputa with 109 cfu/ml BCC, where 3 out of 4 samples
were positive in 108 to 106 cfu/ml concentration range.
Conclusions: BCC detection limit of recA PCR from sputum was 106 cfu/ml.
Diagnostic impact of single-round recA PCR directly from sputum seemed to
be limited to chronically-infected patients where bacterial loads of 107–109 cfu
in sputum was noted. The most efﬁcient molecular detection method for BCC
directly from patients’ sputa need to be determined particularly in the case of
newly colonized patients usually expressing lower bacterial counts.
